3-aminothioxanthen-9-one 10,10-dioxide | 156118-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: 3-aminothioxanthen-9-one 10,10-dioxide
• 英文别名: 3-Amino-10,10-dioxothioxanthen-9-one
• CAS: 156118-87-5
• 化学式: C₁₃H₉NO₃S
• 分子量: 259.285
• InChiKey: HKFAGYLPXJHNIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-aminothioxanthen-9-one 10,10-dioxide 生成 3-(N,N-diformylimino)thioxanthen-9-one 10,10-dioxide
  参考文献：
  名称：

  Harfenist Morton, Joyner Charles T., Mize Patrick D., White Helen L., J. Med. Chem, 37 (1994) N 13, S 2085-2089

  摘要：

  DOI：
• 作为产物：
  描述：

  3-nitrothioxanthen-9-one-10,10-dioxide 在 铂 氢气 、 溶剂黄146 作用下， 生成 3-aminothioxanthen-9-one 10,10-dioxide
  参考文献：
  名称：

  Selective Inhibitors of Monoamine Oxidase. 2. Arylamide SAR

  摘要：

  Monoamine oxidase (MAO) exists in two forms distinguishable by substrate specificity. Inhibition of MAO A is believed to be responsible for the antidepressant activity of MAO inhibitors. A group of N-arylacetamides are highly specific inhibitors of MAO A, some with IC50 values in the 10-100 nM range. The requirements for high activity and specificity include a nearly linear tricyclic aromatic portion but a larger and a smaller central ring component. The amide group, which is best acetamido, is optimally placed para to the smaller central group. The size and shape of the aromatic moiety appear to be the major influence on activity and specificity for MAO A.

  DOI：

  10.1021/jm00039a021

文献信息

• COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
  申请人：PTC Therapeutics, Inc.

  公开号：EP3067053A1

  公开（公告）日：2016-09-14

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。
• <i>N</i>-Aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides:  K_ATP Potassium Channel Openers. Modifications on the Western Region
  作者：Cyrus J. Ohnmacht、Keith Russell、James R. Empfield、Cathy A. Frank、Keith H. Gibson、Daniel R. Mayhugh、Frances M. McLaren、Howard S. Shapiro、Frederick J. Brown、Diane A. Trainor、Christopher Ceccarelli、Margaret M. Lin、Brian B. Masek、Janet M. Forst、Robert J. Harris、James M. Hulsizer、Joseph J. Lewis、Stuart M. Silverman、Reed W. Smith、Paul J. Warwick、Sen T. Kau、Alexa L. Chun、Thomas L. Grant、Burton B. Howe、Jack H. Li、Shephali Trivedi、Tracy J. Halterman、Christopher Yochim、Martin C. Dyroff、M. Kirkland、Kathleen L. Neilson

  DOI：10.1021/jm960365n

  日期：1996.1.1

  A subset of antiandrogen compounds, the N-aryl-3,3,3-trinuoro-2-hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (K-ATP) and represent a new class of potassium channel openers (PCOs). A structure-activity relationship was carried out on the western region of this series with the goal of obtaining an activator of the ATP sensitive potassium channel suitable for use in the treatment of urge urinary incontinence. In particular three large 4-(N-aryl) substituents, the (N-phenyl-N-methylamino)sulfonyl, benzoyl, and 4-pyridylsulfonyl moieties, yielded non-antiandrogen, K-ATP potassium channel openers (39, 41, and 64, respectively) that are bladder selective in an in vivo rat model that simultaneously measures bladder contractions, heart rate, and blood pressure. Substitutions of the aryl rings of 41 and 64 gave several derivatives that also display selectivity in the in vivo rat model; however, none appear to offer a substantial advantage over 41 and 64. The PCO activity of 41 and 64 resides in the (S)-(-) enantiomers. ZD6169, 41(S), has been selected into development for the treatment of urge urinary incontinence.
• Compounds for nonsense suppression, and methods for their use
  申请人：PTC Therapeutics, Inc.

  公开号：EP2311455B1

  公开（公告）日：2015-07-15
• Selective Inhibitors of Monoamine Oxidase. 2. Arylamide SAR
  作者：Morton Harfenist、Charles T. Joyner、Patrick D. Mize、Helen L. White

  DOI：10.1021/jm00039a021

  日期：1994.6

  Monoamine oxidase (MAO) exists in two forms distinguishable by substrate specificity. Inhibition of MAO A is believed to be responsible for the antidepressant activity of MAO inhibitors. A group of N-arylacetamides are highly specific inhibitors of MAO A, some with IC50 values in the 10-100 nM range. The requirements for high activity and specificity include a nearly linear tricyclic aromatic portion but a larger and a smaller central ring component. The amide group, which is best acetamido, is optimally placed para to the smaller central group. The size and shape of the aromatic moiety appear to be the major influence on activity and specificity for MAO A.
• Harfenist Morton, Joyner Charles T., Mize Patrick D., White Helen L., J. Med. Chem, 37 (1994) N 13, S 2085-2089
  作者：Harfenist Morton, Joyner Charles T., Mize Patrick D., White Helen L.

  DOI：——

  日期：——